Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Depreciation & Amortization (CF) (2023 - 2025)

Kura Oncology (KURA) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $403000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 97.55% to $403000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 21.7% increase, with the full-year FY2025 number at $1.0 million, up 21.7% from a year prior.
  • Depreciation & Amortization (CF) was $403000.0 for Q4 2025 at Kura Oncology, up from $164000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $403000.0 in Q4 2025 to a low of $164000.0 in Q3 2025.
  • A 3-year average of $223333.3 and a median of $210500.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 97.55% in 2025; the steepest drop was 21.15% in 2025.
  • Kura Oncology's Depreciation & Amortization (CF) stood at $165000.0 in 2023, then increased by 23.64% to $204000.0 in 2024, then soared by 97.55% to $403000.0 in 2025.
  • Per Business Quant, the three most recent readings for KURA's Depreciation & Amortization (CF) are $403000.0 (Q4 2025), $164000.0 (Q3 2025), and $224000.0 (Q2 2025).